Cerivastatin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Synonyms / Brand Names: Cerivastatin sodium; Cerivastatin, sodium salt; Baycol; Lipobay, Rivastatin
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Dosing and Administration
The starting-dose of BAYCOL® is 0.4 mg once daily in the evening regardless of previous lipid therapy. Since the maximal effect of cerivastatin sodium is seen within 4 weeks lipid determinations should be performed at this time and the dose adjusted based upon patient response. Only patients requiring further lipid adjustment should be titrated to 0.8 mg. The dosage range is 0.2 mg to 0.8 mg. In patients with significant renal impairment (creatinine clearance ≤60 mL/min/1.73m2 ) lower doses are recommended. Cerivastatin sodium may be taken with or without food.
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on Cerivastatin
Return to top
Publication Resources
Most Recent Articles on Cerivastatin
Review Articles on Cerivastatin
Articles on Cerivastatin in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on Cerivastatin
Return to top
Trial Resources
Ongoing Trials with Cerivastatin at Clinical Trials.gov
Trial Results with Cerivastatin
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Cerivastatin
Cochrane Collaboration on Cerivastatin
Cost Effectiveness of Cerivastatin
Return to top
Media Resources
Powerpoint Slides on Cerivastatin
Images of Cerivastatin
Podcasts & MP3s on Cerivastatin
Videos on Cerivastatin
Return to top
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on Cerivastatin
Discussion Groups on Cerivastatin
Patient Handouts on Cerivastatin
Blogs on Cerivastatin
Cerivastatin in the News
Cerivastatin in the Marketplace
Return to top
International Resources
Cerivastatin en Español
Return to top
The content of this page is taken from the FDA package insert for this drug and should not be edited.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
